Iterum Therapeutics Shares Are Surging - Read Why

• Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections.

• The pivotal study under the SPA agreement is designed as a non-inferiority trial comparing oral sulopenem and Augmentin (amoxicillin/clavulanate).

• Related: Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22.

• Patients will be randomized to receive either oral sulopenem twice daily for five days or Augmentin twice daily for five days.

• The primary endpoint is the overall response at Day 12 of the study.

• The study is expected to enroll approximately 1,966 patients and is anticipated to start enrolling in the fourth quarter of 2022.

• The Company has already commenced study start-up activities to enable timely initiation and recruitment.

• Price Action: ITRM shares are up 62.10% at $0.39 during the market session on the last check Monday.

See more from Benzinga

• Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study

• This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.